PRODUCT INFORMATION

Genz-123346

Item No. 28500

CAS Registry No.:	491833-30-8
Formal Name:	N-[(1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]-nonanamide
MF:	$C_{24}H_{38}N_2O_4$
FW:	418.6
Purity:	≥98%
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Genz-123346 is supplied as a crystalline solid. A stock solution may be made by dissolving the genz-123346 in the solvent of choice, which should be purged with an inert gas. Genz-123346 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of genz-123346 in these solvents is approximately 30 mg/ml.

Description

Genz-123346 is a glucosylceramide synthase inhibitor (IC_{50} = 14 nM).[1] It reduces hepatic levels of glucosylceramide and triglycerides as well as blood levels of alanine aminotransferase (ALT), hemoglobin A1c, and non-fasting glucose in *ob/ob* mice when administered at a dose of 120 mg/kg per day.[2] Genz-123346 (125 mg/kg per day) also decreases hepatic fat mass and reduces the size and number of hepatic lipid droplets in diet-induced obese mice.

References

1. Zhao, H., Przybylska, M., Wu, I.-H., *et al.* Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. *Diabetes* **56(5)**, 1210-1218 (2007).
2. Zhao, H., Przybylska, M., Wu, I.-H., *et al.* Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. *Hepatology* **50(1)**, 85-93 (2009).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM